Abstract:Escitalopram is the (S)-enantiomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram. Clinical studies have shown that escitalopram is effective and well tolerated in the treatment of depression and anxiety disorders. Following oral administration, escitalopram is rapidly absorbed and reaches maximum plasma concentrations in approximately 3-4 hours after either single- or multiple-dose administration. The absorption of escitalopram is not affected by food. The elimination half-life of escitalopram is about 27-33 hours and is consistent with once-daily administration. Steady-state concentrations are achieved within 7-10 days of administration. Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs. It is widely distributed throughout tissues, with an apparent volume of distribution during the terminal phase after oral administration (V(z)/F) of about 1100L. Unmetabolised escitalopram is the major compound in plasma. S-demethylcitalopram (S-DCT), the principal metabolite, is present at approximately one-third the level of escitalopram; however, S-DCT is a weak inhibitor of serotonin reuptake and does not contribute appreciably to the therapeutic activity of escitalopram. The didemethyl metabolite of escitalopram (S-DDCT) is typically present at or below quantifiable concentrations. Escitalopram and S-DCT exhibit linear and dose-proportional pharmacokinetics following single or multiple doses in the 10-30 mg/day dose range. Adolescents, elderly individuals and patients with hepatic impairment do not have clinically relevant differences in pharmacokinetics compared with healthy young adults, implying that adjustment of the dosage is not necessary in these patient groups. Escitalopram is metabolised by the cytochrome P450 (CYP) isoenzymes CYP2C19, CYP2D6 and CYP3A4. However, ritonavir, a potent inhibitor of CYP3A4, does not affect the pharmacokinetics of escitalopram. Coadministration of escitalopram 20mg following steady-state administration of cimetidine or omeprazole led to a 72% and 51% increase, respectively, in escitalopram exposure compared with administration alone. These changes were not considered clinically relevant. In vitro studies have shown that escitalopram has negligible inhibitory effects on CYP isoenzymes and P-glycoprotein, suggesting that escitalopram is unlikely to cause clinically significant drug-drug interactions. The favourable pharmacokinetic profile of escitalopram suggests clinical utility in a broad range of patients.

Graphical synthetic routes of Escitalopram

Study on the Industryial Production of Citalopram

An Access to Chiral Phthalides: Enantioselective Synthesis of Escitalopram

Chemo-enzymatic Asymmetric Synthesis of S-citalopram by Lipase-Catalyzed Cyclic Resolution and Stereoinversion of Quaternary Stereogenic Center.

Highly Enantioselective Rhodium-Catalyzed Addition of Arylboroxines to Simple Aryl Ketones: Efficient Synthesis of Escitalopram

Efficient Synthesis of Functionalized 1,3-Dihydroisobenzofurans from Salicylaldehydes: Application to the Synthesis of Escitalopram

Synthesis of antidepressant mirtazapine

Computational Characterization of the Selective Inhibition of Human Norepinephrine and Serotonin Transporters by an Escitalopram Scaffold

Complementary Asymmetric Routes to Fused Tricyclic (R)-2,3,4,4A,5,6-hexahydro-1h-pyrazino[1,2-a]quinolines and (R)-1,2,3,4,5,5A,6,7-octahydro-[1,4]diazepino[1,2-a]quinolines

A Linear and Stereoselective Approach for the Synthesis of Dapoxetine from Benzaldehyde

An Improved Synthesis of the 5-HT1A Receptor Agonist Eptapirone Free Base

Development and validation of a capillary electrophoresis method for the determination of escitalopram and sensitive quantification of its enantiomeric impurity in formulations

The clinical pharmacokinetics of escitalopram

Synthesis of 5-chlorocarbonylphalide

A new shortcut synthesis route for (±)raphidecursinol

Stereoselective enrichment and determination of citalopram enantiomers by cation-selective exhaustive injection and sweeping coupled with cyclodextrin modified electrokinetic chromatography

Pharmaceutical-Oriented Selective Synthesis of Mononitriles and Dinitriles Directly from Methyl(hetero)arenes: Access to Chiral Nitriles and Citalopram

Stereodivergent synthesis of all the four stereoisomers of antidepressant reboxetine

Development of an Efficient and Scalable Biocatalytic Route to (1S,4r)-8-hydroxy-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl Propionate Via Enantioselective Enzymatic Desymmetrization of a Prochiral Diester

Chemoenzymatic Synthesis of Ramosetron Hydrochloride

Asymmetric Total Synthesis of Ent-Heliespirones A & C.